Results 121 to 130 of about 4,166,301 (304)

Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs

open access: yes, 2015
Nicholas Moore,1 Charles Pollack,2 Paul Butkerait2 1Department of Pharmacology, Université de Bordeaux, Bordeaux, France; 2Pfizer Consumer Healthcare, Madison, NJ, USA Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen ...
Moore N, Butkerait P, Pollack C
core  

Extending Service Beyond Active Duty: Generalizability of Rheumatoid Arthritis Research Conducted Among US Veterans

open access: yesArthritis Care &Research, EarlyView.
Biomedical research involving US veterans continues to advance health care beyond the Veterans Health Administration. This is particularly true in rheumatoid arthritis (RA), where veteran‐centric research has uncovered novel insights into pathogenesis, risk factors, and disease manifestations, informing clinical care and research across both veteran ...
Austin M. Wheeler   +20 more
wiley   +1 more source

Spontaneous Reporting of Adverse Drug Reactions

open access: yes, 2018
Drugs are used for the benefit of the patient however drugs also produce adverse drug reactions. Adverse drug reaction is an adverse drug event that results in undesirable or unexpected event that requires some changes in the clinician's care of the ...
Jagminder Kaur Bajaj   +1 more
core   +1 more source

Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. Methods One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on ...
May Shuen Tang   +4 more
wiley   +1 more source

Pediatric Adverse Drug Reactions – What’s the Risk?

open access: yes, 2017
Medications are critical to treat diseases. Unfortunately medications do not come without risks and their use can result in adverse drug reactions. Listen in as Jennifer Goldman MD, MS discusses the importance that providers understand how to classify ...
Goldman, Jennifer, Smith, Michael
core   +1 more source

Awareness among nurses about reporting of adverse drug reactions in Sweden.

open access: yes, 2012
BACKGROUND: The purpose of this study was to investigate awareness among nurses regarding their new role as reporters of adverse drug reactions in Sweden and factors that may influence reporting by nurses.
Petersson, Göran   +7 more
core   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

open access: yesArthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi   +10 more
wiley   +1 more source

Adverse drug reactions as a cause for admissions to a department of internal medicine

open access: yes, 2002
PURPOSE: To assess the occurrence and pattern of adverse drug reactions as a cause for acute hospital admission.METHODS: In 681 randomly selected patients, acutely admitted to a clinic of internal medicine at a Swedish university hospital, information ...
Boman, Marit Danell,   +6 more
core   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy